ImmuPharma Historical Income Statement

Stocks . UK . 
Stock . ImmuPharma PLC
IMM Stock   1.12  0.01  0.88%   
Historical analysis of ImmuPharma PLC income statement accounts such as Selling General Administrative of 1.7 M or Other Operating Expenses of 5.1 M can show how well ImmuPharma PLC performed in making a profits. Evaluating ImmuPharma PLC income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ImmuPharma PLC's future profits or losses.
Cash Flow   Balance Sheet     Income Statement
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining ImmuPharma PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ImmuPharma PLC is a good buy for the upcoming year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuPharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About ImmuPharma Income Statement Analysis

ImmuPharma PLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ImmuPharma PLC shareholders. The income statement also shows ImmuPharma investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Balance Sheet
Statement
Details
Cash Flow
Statement
Details

ImmuPharma PLC Income Statement Chart

At present, ImmuPharma PLC's Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 5.1 M, whereas Interest Expense is forecasted to decline to 1,887.
Depreciation And Amortization  Other Operating Expenses  Research Development  Net Income From Continuing Ops  Interest Income  
Add Fundamental

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ImmuPharma PLC. It is also known as ImmuPharma PLC overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.
Most accounts from ImmuPharma PLC's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ImmuPharma PLC current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuPharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
At present, ImmuPharma PLC's Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 5.1 M, whereas Interest Expense is forecasted to decline to 1,887.
 2021 2022 2023 2024 (projected)
Interest Expense2.4M1.5M2.0K1.9K
Depreciation And Amortization114.1K117.6K37.6K35.7K

ImmuPharma PLC income statement Correlations

Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income
Income Tax Expense
Total Revenue
Gross Profit
Research Development
Cost Of Revenue
Net Income From Continuing Ops
Tax Provision
Net Interest Income
Interest Income
Reconciled Depreciation
Selling And Marketing Expenses
Depreciation And Amortization
0.450.110.66-0.72-0.73-0.720.66-0.77-0.33-0.76-0.560.70.440.6-0.41-0.680.24-0.510.550.490.45
Interest Expense
0.45-0.240.04-0.2-0.44-0.430.04-0.52-0.97-0.54-0.140.140.130.01-0.12-0.570.42-0.690.560.140.21
Selling General Administrative
0.11-0.240.44-0.36-0.28-0.280.44-0.230.29-0.23-0.160.090.210.05-0.70.09-0.170.17-0.090.170.04
Other Operating Expenses
0.660.040.44-0.96-0.87-0.871.0-0.860.04-0.84-0.720.50.410.86-0.63-0.670.230.050.090.090.06
Operating Income
-0.72-0.2-0.36-0.960.960.96-0.960.940.090.930.74-0.55-0.48-0.840.60.79-0.15-0.03-0.08-0.2-0.27
Ebit
-0.73-0.44-0.28-0.870.961.0-0.870.990.340.990.67-0.55-0.52-0.750.550.89-0.250.1-0.17-0.2-0.28
Ebitda
-0.72-0.43-0.28-0.870.961.0-0.870.990.340.990.67-0.55-0.52-0.750.550.89-0.250.09-0.16-0.2-0.27
Total Operating Expenses
0.660.040.441.0-0.96-0.87-0.87-0.860.04-0.84-0.720.50.410.86-0.63-0.670.230.050.090.090.06
Income Before Tax
-0.77-0.52-0.23-0.860.940.990.99-0.860.421.00.7-0.51-0.44-0.740.580.88-0.320.21-0.26-0.17-0.25
Total Other Income Expense Net
-0.33-0.970.290.040.090.340.340.040.420.450.08-0.02-0.030.070.110.47-0.540.66-0.540.05-0.02
Net Income
-0.76-0.54-0.23-0.840.930.990.99-0.841.00.450.64-0.5-0.47-0.70.560.9-0.340.23-0.29-0.19-0.26
Income Tax Expense
-0.56-0.14-0.16-0.720.740.670.67-0.720.70.080.64-0.41-0.09-0.820.60.43-0.05-0.060.070.05-0.07
Total Revenue
0.70.140.090.5-0.55-0.55-0.550.5-0.51-0.02-0.5-0.410.810.53-0.16-0.51-0.09-0.020.030.430.39
Gross Profit
0.440.130.210.41-0.48-0.52-0.520.41-0.44-0.03-0.47-0.090.810.28-0.05-0.55-0.030.1-0.040.390.35
Research Development
0.60.010.050.86-0.84-0.75-0.750.86-0.740.07-0.7-0.820.530.28-0.39-0.620.10.14-0.080.030.03
Cost Of Revenue
-0.41-0.12-0.7-0.630.60.550.55-0.630.580.110.560.6-0.16-0.05-0.390.14-0.240.09-0.10.130.11
Net Income From Continuing Ops
-0.68-0.570.09-0.670.790.890.89-0.670.880.470.90.43-0.51-0.55-0.620.14-0.280.22-0.28-0.3-0.38
Tax Provision
0.240.42-0.170.23-0.15-0.25-0.250.23-0.32-0.54-0.34-0.05-0.09-0.030.1-0.24-0.28-0.540.61-0.49-0.49
Net Interest Income
-0.51-0.690.170.05-0.030.10.090.050.210.660.23-0.06-0.020.10.140.090.22-0.54-0.95-0.27-0.16
Interest Income
0.550.56-0.090.09-0.08-0.17-0.160.09-0.26-0.54-0.290.070.03-0.04-0.08-0.1-0.280.61-0.950.270.14
Reconciled Depreciation
0.490.140.170.09-0.2-0.2-0.20.09-0.170.05-0.190.050.430.390.030.13-0.3-0.49-0.270.270.84
Selling And Marketing Expenses
0.450.210.040.06-0.27-0.28-0.270.06-0.25-0.02-0.26-0.070.390.350.030.11-0.38-0.49-0.160.140.84
Click cells to compare fundamentals

ImmuPharma PLC Account Relationship Matchups

High Positive Relationship

Total Operating Expenses
+ 1.0
Other Operating Expenses
Ebitda
+ 1.0
Ebit
Net Income
+ 1.0
Income Before Tax
Income Before Tax
+ 0.99
Ebit
Net Income
+ 0.99
Ebit
Income Before Tax
+ 0.99
Ebitda

High Negative Relationship

Total Other Income Expense Net
- 0.97
Interest Expense
Total Operating Expenses
- 0.96
Operating Income
Operating Income
- 0.96
Other Operating Expenses
Interest Income
- 0.95
Net Interest Income
Total Operating Expenses
- 0.87
Ebitda
Total Operating Expenses
- 0.87
Ebit

ImmuPharma PLC income statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization90.3K171.0K114.1K117.6K37.6K35.7K
Interest Expense526.7K1.7M2.4M1.5M2.0K1.9K
Selling General Administrative1.8M1.8M1.0M846.6K1.0M1.7M
Other Operating Expenses6.4M5.7M5.3M3.0M3.1M5.1M
Operating Income(6.3M)(5.6M)(6.6M)(3.0M)(3.1M)(3.2M)
Ebit(6.7M)(7.0M)(8.8M)(3.0M)(3.1M)(3.2M)
Ebitda(6.7M)(6.8M)(8.7M)(2.9M)(3.0M)(3.2M)
Total Operating Expenses6.4M5.7M5.3M3.0M3.1M5.1M
Income Before Tax(6.7M)(7.2M)(8.9M)(4.5M)(3.4M)(3.6M)
Total Other Income Expense Net(462.7K)(1.7M)(2.4M)(1.4M)(355.9K)(338.1K)
Net Income(6.1M)(6.9M)(8.2M)(3.8M)(2.9M)(3.1M)
Income Tax Expense(620.8K)(386.2K)(766.8K)(648.9K)(497.1K)(522.0K)
Gross Profit77.9K126.7K118.4K(117.6K)(37.6K)(35.7K)
Research Development2.7M2.4M3.7M2.0M2.0M3.0M
Net Income Applicable To Common Shares(7.2M)(6.1M)(6.9M)(8.2M)(7.4M)(7.0M)
Net Income From Continuing Ops(6.1M)(6.9M)(8.2M)(3.8M)(2.9M)(3.1M)
Tax Provision(620.8K)(386.2K)(766.8K)(648.9K)(497.1K)(522.0K)
Net Interest Income1.7K(1.7M)(205.2K)(1.4M)1.0K1.1K
Interest Income5.7K41.1K651.028.6K3.0K2.9K
Reconciled Depreciation88.0K171.0K114.1K117.6K37.6K35.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor

Other Information on Investing in ImmuPharma Stock

ImmuPharma PLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ImmuPharma PLC shareholders. The income statement also shows ImmuPharma investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Balance Sheet
Statement
Details
Cash Flow
Statement
Details
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY